TY - JOUR T1 - Eradication of early MRSA infection in cystic fibrosis – a novel study design for “STAR-ter” trial JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00190-2022 SP - 00190-2022 AU - Fiona Cunningham AU - Ellen Caldwell AU - Nicole Mayer-Hamblett AU - Christopher H. Goss AU - Marianne S. Muhlebach Y1 - 2022/01/01 UR - http://openres.ersjournals.com/content/early/2022/08/18/23120541.00190-2022.abstract N2 - Cystic Fibrosis (CF), is an autosomal recessive disease that affects approximately 34,000 people in the U.S. Those living with CF produce abnormally viscous mucus, resulting in chronic bacterial lung infections [1]. Pulmonary infection and the resultant lung disease are the leading cause of death for CF patients [2]. Several bacteria are associated with higher mortality, including P. aeruginosa, Burkholderia cepacia and methicillin-resistant Staphylococcus aureus (MRSA) [3]. MRSA is also a risk for increased rates of hospitalization and failure to recover baseline lung function after IV antibiotics for pulmonary exacerbations [4]. Conversely, MRSA could be a marker of worse underlying disease. Within 2 years after MRSA acquisition there was no disease progression but was associated with more intense therapies [5, 6]. Of note, that all those studies were done before availability of highly effective modulator therapies (HEMT).FootnotesThis manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.Conflicts of interest: The authors report no relevant conflicts of interest ER -